The final maturation of at least some single-positive CD4hi thymocytes does not require T cell receptor-major histocompatibility complex contact

被引:11
作者
Dyall, R
Nikolic-Zugic, J
机构
[1] Mem Sloan Kettering Canc Ctr, Program Immunol, Lab T Cell Dev, New York, NY 10021 USA
[2] Cornell Univ, Weil Grad Sch Med Sci, New York, NY 10021 USA
关键词
CD4; thymocytes; T cell receptor; T cell development; major histocompatibility complex class II;
D O I
10.1084/jem.190.6.757
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The majority (similar to 70%) of postselection CD4+ single-positive (SP) thymocytes are CD8(lo)CD4(hi). These cells express very low levels of CD8, undetectable by now cytofluorimetric (FCM) analysis, but sufficiently high to allow purification by panning. Unlike the fully mature CD8-CD4(hi) thymocyte, which account for the remaining similar to 30% of the SP CD4(+) thymocytes, CD8(lo)CD4(hi) cells are functionally immature and short-lived unless they receive an unidentified maturation signal from the thymus. In this study, we tested the hypothesis that this signal is provided by a T cell receptor (TCR)-major histocompatibility complex (MHC) class II interaction. Using intrathymic transfer, we show that the immature CD8(lo)CD4(hi) cells could complete their intrathymic maturation and populate the peripheral lymphoid organs in the absence of MHC class II land class I) molecules. Furthermore, in mice devoid of class II land class I) molecules, the progeny of CD8(lo)CD4(hi) cells was long-lived and functionally reactive to allogeneic class II molecules, although their numbers in the spleen and the mesenteric lymph node were similar to 40-50% lower than those in class II+ mice 5 mo after transfer. Control experiments demonstrated that the surviving cells did not originate from the contaminating mature thymocytes. These results demonstrate that the final maturation, proliferation, and peripheral survival (up to 5 mo) of at least some postselection CD4(+) SP cells do not require the TCR-MHC class II interaction. They also indicate that the TCR-MHC class II interaction(s) required for the intrathymic development of long-lived CD4(+) SP cells occurs before the CD4(hi) SP stage of development.
引用
收藏
页码:757 / 764
页数:8
相关论文
共 34 条
[1]   From stem cells to lymphocytes: Biology and transplantation [J].
Aguila, HL ;
Akashi, K ;
Domen, J ;
Gandy, KL ;
Lagasse, E ;
Mebius, RE ;
Morrison, SJ ;
Shizuru, J ;
Strober, S ;
Uchida, N ;
Wright, DE ;
Weissman, IL .
IMMUNOLOGICAL REVIEWS, 1997, 157 :13-40
[2]   Immunology - Selection for survival? [J].
Benoist, C ;
Mathis, D .
SCIENCE, 1997, 276 (5321) :2000-2001
[3]   Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II-expressing dendritic cells [J].
Brocker, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (08) :1223-1232
[4]   THE MAJORITY OF POSTSELECTION CD4(+) SINGLE-POSITIVE THYMOCYTES REQUIRES THE THYMUS TO PRODUCE LONG-LIVED, FUNCTIONAL T-CELLS [J].
DYALL, R ;
NIKOLICZUGIC, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (01) :235-245
[5]   THYMIC SELECTION AND CELL-DIVISION [J].
ERNST, B ;
SURH, CD ;
SPRENT, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (04) :961-971
[6]   Recent thymic emigrants are distinct from most medullary thymocytes [J].
Gabor, MJ ;
Godfrey, DI ;
Scollay, R .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (08) :2010-2015
[7]   STUDIES OF THYMOCYTOPOIESIS IN RATS AND MICE .1. KINETICS OF APPEARANCE OF THYMOCYTES USING A DIRECT INTRATHYMIC ADOPTIVE TRANSFER ASSAY FOR THYMOCYTE PRECURSORS [J].
GOLDSCHNEIDER, I ;
KOMSCHLIES, KL ;
GREINER, DL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 163 (01) :1-17
[8]   DEPLETION OF CD4+ T-CELLS IN MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II DEFICIENT MICE [J].
GRUSBY, MJ ;
JOHNSON, RS ;
PAPAIOANNOU, VE ;
GLIMCHER, LH .
SCIENCE, 1991, 253 (5026) :1417-1420
[9]   T-CELL RECEPTOR-MEDIATED NEGATIVE SELECTION OF AUTOREACTIVE LYMPHOCYTE-T PRECURSORS OCCURS AFTER COMMITMENT TO THE CD4 OR CD8 LINEAGES [J].
GUIDOS, CJ ;
DANSKA, JS ;
FATHMAN, CG ;
WEISSMAN, IL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (03) :835-845
[10]  
Hare KJ, 1999, J IMMUNOL, V162, P3978